Somatotropin ( DrugBank: Somatotropin )


4 diseases
IDDisease name (Link within this page)Number of trials
3Spinal muscular atrophy1
65Primary immunodeficiency1
78Hypopituitarism4
236Pseudohypoparathyroidism1

3. Spinal muscular atrophy


Clinical trials : 237 Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00533221
(ClinicalTrials.gov)
October 200712/9/2007Pilot Study of Growth Hormon to Treat SMA Typ II and IIICan Treatment With Human Growth Hormone Increase Strength in Spinal Muscular Atrophy Type II and III?Muscular Atrophy, SpinalDrug: somatotropin;Drug: PlaceboUniversity Hospital FreiburgNovo Nordisk A/SCompleted6 Years35 YearsBoth20Phase 2Germany

65. Primary immunodeficiency


Clinical trials : 500 Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-015739-34-DE
(EUCTR)
09/12/200914/09/2009Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT) - Growth hormone in AT (GHAT)Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT) - Growth hormone in AT (GHAT) This study will evaluate the status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and composition and neuroprotection in children with Ataxia telangiectasia (AT)Trade Name: Catapresan 75, Tabletten
INN or Proposed INN: Clonidinhydrochlorid
Trade Name: L-Arginin-hydrochlorid-einmolar Fresenius
INN or Proposed INN: Argininhydrochlorid
Trade Name: Progynova 21 mite
INN or Proposed INN: Estradiolvalerat
Trade Name: NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung
INN or Proposed INN: Somatotropin
Goethe-Universität Frankfurt/MainNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Germany

78. Hypopituitarism


Clinical trials : 492 Drugs : 341 - (DrugBank : 47) / Drug target genes : 45 - Drug target pathways : 100
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-001674-32-FI
(EUCTR)
29/04/200925/08/2008NordiNet International Outcome Study (NordiNet IOS) - NordiNet IOSNordiNet International Outcome Study (NordiNet IOS) - NordiNet IOS Small Gestation Age, Turner Syndrome, Growth Hormone Deficiency
MedDRA version: 16.1;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders
Trade Name: Norditropin
INN or Proposed INN: somatotropine
Novo Nordisk Farma OyNULLNot RecruitingFemale: yes
Male: yes
17000Phase 4Finland
2NCT01576861
(ClinicalTrials.gov)
January 200719/3/2012Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart FailureGrowth Hormone Deficiency;Chronic Heart FailureDrug: SomatotropinFederico II UniversityNULLCompleted18 Years80 YearsBoth28Phase 2Italy
3NCT00591760
(ClinicalTrials.gov)
December 200420/12/2007Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary TrialCorrection of Growth Hormone Deficiency in Patients With Chronic Heart Failure: a Randomized, Controlled, Single-blind StudyHeart Failure;Growth Hormone Deficiency;Ischemic Heart DiseaseDrug: SomatotropinFederico II UniversityNULLCompleted18 Years80 YearsAll56Phase 2NULL
4NCT00497484
(ClinicalTrials.gov)
February 19955/7/2007Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)Pseudohypoparathyroidism;Growth Hormone Deficiency, DwarfismDrug: recombinant human somatotropinUniversity of MilanEli Lilly and CompanyActive, not recruiting1 Year18 YearsBothN/AItaly

236. Pseudohypoparathyroidism


Clinical trials : 3 Drugs : 3 - (DrugBank : 2) / Drug target genes : 18 - Drug target pathways : 23
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00497484
(ClinicalTrials.gov)
February 19955/7/2007Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)Pseudohypoparathyroidism;Growth Hormone Deficiency, DwarfismDrug: recombinant human somatotropinUniversity of MilanEli Lilly and CompanyActive, not recruiting1 Year18 YearsBothN/AItaly